Skip to main content

Can you take Elagolix with Revuforj?

1 drug interaction and 12 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

elagolix revumenib

Applies to: elagolix and Revuforj (revumenib)

Elagolix may reduce the blood levels of revumenib, which may make the medication less effective in some cases.

Using elagolix with revumenib may also increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)

You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications. Contact your doctor if your symptoms worsen or your condition changes.

Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

Moderate food/lifestyle interactions

Moderate:

revumenib Food/Lifestyle

Applies to: Revuforj (revumenib)

High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat).

Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.

You may be more susceptible if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)

Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.

Symptoms of differentiation syndrome include:

  • fever
  • cough
  • shortness of breath
  • severe headache
  • confusion
  • dizziness
  • rapid weight gain
  • swelling
  • decreased urination

You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.

The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib.

Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Disease interactions

11 potential interactions Applies to: 10 conditions, including Depression, Anxiety and Stress, Heart Failure, Osteoporosis, and Arrhythmia.

Anxiety and Stress

Moderate:

elagolix

Elagolix has a moderate potential interaction with Anxiety and Stress.

Suicidal ideation and behavior, has been reported in women treated with elagolix in the endometriosis clinical trials. Women with a history of suicidality or depression had a higher incidence of depression compared to women without such a history. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional. Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing elagolix if such events occur.

Arrhythmia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Arrhythmia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Depression

Moderate:

elagolix

Elagolix has a moderate potential interaction with Depression.

Suicidal ideation and behavior, has been reported in women treated with elagolix in the endometriosis clinical trials. Women with a history of suicidality or depression had a higher incidence of depression compared to women without such a history. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional. Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing elagolix if such events occur.

Heart Failure

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Heart Failure.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Hypokalemia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Hypokalemia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Liver Disease

Major:

elagolix

Elagolix has a major potential interaction with Liver Disease.

Compared to women with normal liver function, those with moderate hepatic impairment had approximately 3-fold higher elagolix exposures and those with severe hepatic impairment had approximately 7-fold higher elagolix exposures. Because of these increased exposures and risk for bone loss, the use of elagolix is contraindicated in women with severe hepatic impairment (Child-Pugh C). In women with moderate hepatic impairment (Child-Pugh B) elagolix 150 mg is recommended once daily with the duration of treatment limited to 6 months. No dose adjustment is needed for women with mild hepatic impairment (Child-Pugh A).

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Liver Disease.

Revumenib has not been studied in patients with severe liver or renal impairment.

Long QT Syndrome

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Long QT Syndrome.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Magnesium Imbalance

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Magnesium Imbalance.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Osteoporosis

Major:

elagolix

Elagolix has a major potential interaction with Osteoporosis.

Elagolix is contraindicated in women with known osteoporosis because of the risk of further bone loss. Elagolix causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.

Renal Dysfunction

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Renal Dysfunction.

Revumenib has not been studied in patients with severe liver or renal impairment.

Report options

Loading...
QR code containing a link to this page

More resources

elagolix

A total of 429 drugs are known to interact with elagolix.

Revuforj

A total of 583 drugs are known to interact with Revuforj.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer